A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality.

Bisphosphite ligands based on benzopinacol with an open outer unit, and the use thereof in hydroformylation.

This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.

Described are compounds that act as AKR1C3 inhibitors or pharmaceutically acceptable salts or solvates or isotopically substituted compounds thereof and methods thereof.

According to an embodiment of the present inventive concept, an electrolyte additive represented by the compounds of Chemical Formulas 1 to 4 may be provided. In addition, according to another embodiment of the present inventive concept, a method for preparing an electrolyte additive of the compounds of Chemical Formulas 1 to 4 may be provided, wherein the method for preparing the electrolyte additive includes reacting hexafluorophosphate and 2-monofluoromalonic acid, further adding an HF scavenger to the mixed solution produced by the reaction, and concentrating and drying the reaction solution obtained therefrom.

Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, and wherein at least one of R.sup.1, R.sup.2 and R.sup.3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided. ##STR00001##

Provided herein are organophosphates and pharmaceutical compositions comprising said compounds.

Polyolefin compositions comprising i) a polyolefin, ii) one or more phosphorus-containing benzofuranone compounds and iii) one or more hindered phenolic antioxidants are provided excellent protection against discoloration and enhanced thermal stability during melt processing as exhibited by improved retention of molecular weight and maintenance of polymer molecular architecture.

A method for preparing the cyclic phosphonate compound of Formula I ##STR00001##
is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.